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The Urokinase Receptor Induces 
a Mesenchymal Gene Expression 
Signature in Glioblastoma Cells and 
Promotes Tumor Cell Survival in 
Neurospheres
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PLAUR encodes the urokinase receptor (uPAR), which promotes cell survival, migration, and resistance 
to targeted cancer therapeutics in glioblastoma cells in culture and in mouse model systems. Herein, 
we show that patient survival correlates inversely with PLAUR mRNA expression in gliomas of all 
grades, in glioblastomas, and in the subset of glioblastomas that demonstrate the mesenchymal 
gene expression signature. PLAUR clusters with genes that define the more aggressive mesenchymal 
subtype in transcriptome profiles of glioblastoma tissue and glioblastoma cells in neurospheres, which 
are enriched for multipotent cells with stem cell-like qualities. When PLAUR was over-expressed or 
silenced in glioblastoma cells, neurosphere growth and expression of mesenchymal subtype biomarkers 
correlated with uPAR abundance. uPAR also promoted glioblastoma cell survival in neurospheres. 
Constitutively-active EGF Receptor (EGFRvIII) promoted neurosphere growth; however, unlike uPAR, 
EGFRvIII did not induce the mesenchymal gene expression signature. Immunohistochemical analysis of 
human glioblastomas showed that uPAR is typically expressed by a small sub-population of the cancer 
cells; it is thus reasonable to conclude that this subpopulation of cells is responsible for the effects 
of PLAUR on patient survival. We propose that uPAR-expressing glioblastoma cells demonstrate a 
mesenchymal gene signature, an increased capacity for cell survival, and stem cell-like properties.
Epithelial-mesenchymal transition (EMT) and mesenchymal-epithelial transition are necessary processes in nor-
mal embryogenesis1. When a cell acquires a mesenchymal phenotype, it demonstrates increased capacity for 
cell migration and invasion, resistance to apoptosis, and properties of stem cells1,2. EMT has been demonstrated 
in cancer cells in culture and in pre-clinical animal models of cancer. In these contexts, cancer cells that have 
undergone EMT demonstrate increased cell migration, invasion, and metastasis3,4. Although the significance 
of EMT in human malignancies has been questioned, EMT has been demonstrated in circulating tumor cells in 
human blood, indicating that this transformation occurs in human cancers at least under some circumstances5. 
Understanding the molecular pathways that drive EMT in cancer remains an important problem.
The PLAUR gene product, uPAR, is a glycosyl-phosphatidylinositol-anchored membrane protein that binds 
the serine proteinase, urokinase-type plasminogen activator (uPA), and activates a cascade of extracellular pro-
teinases that function in tissue remodeling6–8. At the same time, uPAR associates with integrins and receptor 
tyrosine kinases in the plasma membrane to form a potent multiprotein cell-signaling complex9–11. In breast 
cancer cells, uPAR-activated cell-signaling induces EMT12,13, together with many of the changes identified in 
non-malignant cells that undergo EMT, including increased capacity for cell migration14,15, resistance to apop-
tosis16–18, and stem cell-like properties19. Although uPA-binding amplifies uPAR-activated cell-signaling and 
1Department of Pathology, University of California San Diego, La Jolla, California, 92093, USA. 2Department of 
Experimental Medicine, Sapienza University of Rome, Rome, Italy. Correspondence and requests for materials 
should be addressed to S.L.G. (email: sgonias@ucsd.edu)
Received: 20 October 2017
Accepted: 2 February 2018
Published: xx xx xxxx
OPEN
www.nature.com/scientificreports/
2Scientific REPORTS |  (2018) 8:2982  | DOI:10.1038/s41598-018-21358-1
expands the scope of cell-signaling factors activated9–11,14, uPAR also signals independently of uPA and promotes 
cancer metastasis in preclinical animal models when uPA-binding is not possible20–22.
Despite recent advances in treatment, grade IV gliomas/glioblastomas still carry a very poor prognosis23,24. 
Genetic, epigenetic, and transcriptome profiling studies have revealed extensive heterogeneity in glioblasto-
mas25–28. As a result, attempts have been made to sub-classify these tumors using profiling results. Verhaak et al.28 
analyzed transcriptome profiling data and classified glioblastomas as classical, proneural, neural, or mesenchy-
mal. The mesenchymal subtype of glioblastoma expresses high levels of genes that are biomarkers of EMT and 
also genes expressed by Schwann cells and microglia. Mesenchymal glioblastomas may have a greater capacity for 
invasion29. Furthermore, the mesenchymal gene expression signature is selectively observed in circulating glio-
blastoma cells in the blood30. One limitation in applying classification schemes in glioblastoma is the diversity in 
gene expression profiles observed in individual tumor cells in a single cancer31. We hypothesized that cells within 
a glioblastoma that demonstrate a mesenchymal gene expression signature may be the most aggressive.
PLAUR has been characterized as a gene expressed selectively by mesenchymal glioblastomas28. This is intrigu-
ing because, in cell culture and animal model systems, uPAR promotes glioblastoma cell survival, cell migration, 
and resistance to targeted cancer therapies32–34. The role of uPAR in human glioblastoma in patients remains less 
clearly defined. Herein, we demonstrate that high levels of PLAUR mRNA expression correlate inversely with 
patient survival when Grade II, III, and IV gliomas are considered collectively, when glioblastomas are examined, 
and when only glioblastomas that express a mesenchymal gene expression signature are examined. In immuno-
histochemistry (IHC) studies of human glioblastomas, uPAR was robustly expressed by a small sub-population 
of the cancer cells, suggesting that the effects of PLAUR expression on patient survival in glioblastoma may reflect 
the activity of uPAR in a sub-population of the cancer cells.
To identify pathways by which PLAUR gene expression in occasional tumor cells may affect patient survival, 
we examined glioblastoma cells in neurospheres, which select for multipotent cells with cancer stem cell-like 
properties35–37. We showed that uPAR promotes expression of other genes that serve as biomarkers of the mesen-
chymal glioblastoma subtype. uPAR also promoted neurosphere growth and inhibited glioblastoma cell apoptosis 
in neurospheres. These effects were observed even when the glioblastoma cells expressed a constitutively-active 
variant of the EGF Receptor (EGFRvIII). We propose that PLAUR gene expression in glioblastoma adversely 
affects patient survival by promoting a mesenchymal gene expression profile, by allowing cell survival, and by 
inducing stem cell-like properties in a small sub-population of glioblastoma cells.
Results
PLAUR mRNA expression varies with glioma grade and predicts worsened patient survival. 
Yamamoto et al.38 examined 17 gliomas and first demonstrated that PLAUR expression correlates with tumor 
grade. Salajegheh et al.39 analyzed 65 diverse primary brain tumors and also noted the association between PLAUR 
expression and tumor grade. In the current study, we mined microarray gene expression data in The Cancer 
Genome Atlas (TCGA) comparing PLAUR mRNA expression in 981 Grade II, III, and IV gliomas40. PLAUR 
mRNA expression was significantly increased in Grade III gliomas, compared with Grade II gliomas (p < 0.001), 
and further increased in Grade IV gliomas/glioblastomas compared with grade III gliomas (p < 0.001) (Fig. 1A). 
When the cases in this dataset40 were stratified according to PLAUR mRNA expression and those in the top 25% 
were compared with those in the bottom 25%, high levels of PLAUR mRNA significantly predicted worsened 
patient survival, as determined by Log-rank test (p < 0.0001) (Fig. 1B).
Next, we analyzed RNA-Seq mRNA expression data in a TCGA dataset of 151 patients with glioblastoma27. 
RNA-Seq measures mRNA quantitatively over an increased dynamic range41. Figure 1C shows that, in a cohort con-
sisting exclusively of patients with glioblastoma, patient survival was significantly decreased when PLAUR mRNA 
expression was above the median level compared with cases in which PLAUR expression was below the median level 
(p = 0.0017). Patient survival was further decreased when PLAUR mRNA expression was in the top 5% (p = 0.0007). 
In this dataset, six glioblastomas were characterized as CpG island methylator phenotype (GCIMP) tumors, which 
are associated with improved patient survival29,42,43. In five of six GCIMP tumors, PLAUR mRNA expression was 
below the median value for the entire 151 case dataset. When the GCIMP tumors were omitted, the association 
between PLAUR mRNA expression and decreased patient survival was still observed (p = 0.0083) (Fig. 1D).
Increased PLAUR mRNA expression is associated with decreased patient survival in the mes-
enchymal subtype of glioblastoma. Analysis of RNA-Seq data27 demonstrated that PLAUR mRNA 
expression is significantly increased in the mesenchymal subtype of glioblastoma, compared with the proneural 
(p < 0.0001), neural (p < 0.001), and classical (p < 0.001) subtypes of glioblastoma (Fig. 2A,B). A silhouette plot 
shows the strong positive correlation between PLAUR mRNA expression and expression of other mesenchymal 
signature genes (Fig. 2C). Positive and negative correlations (above and below the baseline) were observed when 
PLAUR mRNA expression was compared with genes that define the neural and classical subtypes. A profoundly 
negative correlation was observed when PLAUR was compared with genes that define the proneural subtype.
To assure that PLAUR was not influencing patient survival in glioblastoma because it serves as a surrogate bio-
marker of other co-regulated genes in the mesenchymal gene signature, we analyzed patient survival selectively 
in mesenchymal glioblastomas27. Figure 2D shows that when patients with the mesenchymal subtype of glioblas-
toma were stratified according to PLAUR mRNA expression and those in the top 25% were compared with those 
in the bottom 25%, high levels of PLAUR mRNA significantly predicted worsened patient survival, as determined 
by Log-rank test (p = 0.004).
uPAR protein is expressed by a sub-population of cancer cells in human glioblastomas. Given 
the correlation between PLAUR mRNA expression and patient survival in glioblastoma, we undertook studies 
to examine uPAR protein expression in human glioblastomas by immunohistochemistry (IHC). We examined 
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14 tumors, without patient identifiers, surgically resected at the University of California San Diego Hospital 
and diagnosed by clinical neuropathologists. uPAR was detected in at least some cancer cells in each specimen; 
however, the frequency of uPAR-immunopositive cells was variable from tumor to tumor and within different 
regions of the same tumor. Most frequently, uPAR immunopositive tumor cells were embedded amongst numer-
ous uPAR-immunonegative cells, as determined by hematoxylin counterstaining (Fig. 3A). The high power field 
shown in Fig. 3B is from the same tumor imaged in Fig. 3A; the area imaged in Fig. 3B shows a substantially 
increased density of uPAR-immunopositive cells, compared with other regions of the same tumor. Images of four 
other representative tumors are shown in Fig. 3C–F. The image shown in Fig. 3F shows an area of a glioblastoma 
in which the tumor cells adopted spindle-cell morphology and also were robustly uPAR-immunopositive. We 
previously demonstrated that uPAR immunostaining is fairly uniform amongst human glioblastoma cells that are 
propagated in xenografts32. The studies presented here show that in resected human glioblastomas, prior to xen-
ografting, uPAR immunostaining is quite heterogeneous. Furthermore, these results suggest that the correlation 
between PLAUR mRNA expression and patient survival in glioblastoma may reflect the activity of uPAR protein 
in a small sub-population of the cancer cells.
PLAUR expression is increased in glioblastoma cells that express the mesenchymal gene sig-
nature in neurosphere culture. To determine how PLAUR expression in a small sub-population of glio-
blastoma cells may influence tumor aggressiveness, we studied glioblastoma cells in neurosphere culture. This 
culturing method selects for glioblastoma cells with tumor-initiating or cancer stem cell-like properties; glioblas-
toma cells in neurospheres have an increased capacity for self-renewal and the ability to recapitulate the heteroge-
neity in the original tumor when transplanted into mice35–37,44,45. Neurosphere culture eliminates contamination 
by non-tumor cells, which contributes to the results obtained when gene expression is examined in intact tumor 
samples.
Figure 1. uPAR expression correlates with patient survival in gliomas. (A) TCGA data were mined. The 
relative quantity (RQ) of PLAUR mRNA is shown for grade II, III, and IV gliomas (***p < 0.001; one way 
ANOVA with Bonferroni’s multiple comparison test). (B) Kaplan-Meier survival curves were generated from 
TCGA data, comparing grades II-IV glioma patients collectively. Cases were stratified to compare the 25% 
in which the tumors demonstrated the highest PLAUR mRNA expression levels with the 25% in which the 
tumors demonstrated the lowest PLAUR mRNA expression levels. Statistical significance was determined using 
the Log-rank test. (C) Kaplan-Meier patient survival curves were generated using TCGA RNA-Seq data and 
comparing glioblastoma cases in which PLAUR mRNA expression was above or below the median expression 
level. Cases in the top 5% for PLAUR mRNA expression also were evaluated. Statistical significance was 
determined by Log-rank test. (D) Kaplan-Meier survival curves were generated as described in panel C, but 
with GCIMP tumors omitted from the analysis.
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Mao et al.46 profiled the transciptomes of ten neurosphere cultures established with cells isolated from differ-
ent surgically-resected human glioblastomas and characterized the cells in these neurospheres as mesenchymal 
or proneural. Cells in neurospheres with mesenchymal gene expression signatures were more aggressive and 
radiation-resistant. Prominent biomarkers of mesenchymal glioblastoma cells in neurosphere culture included 
CD44, BCL2A1, and LYN46–48. Biomarkers of the proneural subtype included SOX2, CD133, and NOTCH146–48. 
We mined the dataset collected by Mao et al.46, and demonstrated that PLAUR mRNA expression clearly sorts with 
genes that define the mesenchymal subtype (Fig. 4A). PLAU, which encodes the ligand for uPAR, urokinase-type 
plasminogen activator (uPA), also sorted with the mesenchymal gene signature. Figure 4B shows that expression 
of PLAU and PLAUR in glioblastoma cells in mesenchymal neurospheres was significantly increased compared 
with cells in proneural neurospheres, as determined by the false discovery rate method (p < 0.001).
Figure 2. PLAUR mRNA expression correlates inversely with patient survival in cases of glioblastoma that 
demonstrate a mesenchymal gene expression signature. (A) Relative PLAUR mRNA expression is shown for 
glioblastomas previously characterized as: mesenchymal (Mes); proneural (PN); neural (N) and classical (C) 
(***p < 0.001; **p < 0.01; one way ANOVA with Tukey’s post hoc test). (B) Distribution of glioblastomas into the 
four subtypes is compared when 151 cases are stratified according to PLAUR mRNA expression as follows: 25% 
of the cases with the lowest level of PLAUR mRNA expression; 25% of the cases with the highest level of PLAUR 
mRNA expression; 10% of the cases with the highest level of PLAUR mRNA expression and; 5% of the cases 
with the highest level of PLAUR mRNA expression. (C) Silhouette plot showing correlations between PLAUR 
expression and 685 genes that serve as biomarkers of the four glioblastoma subtypes. The plot is a condensed 
series of bar graphs corresponding with ascending Pearson r-values for each subtype. Regions above the x-axis 
demonstrate a positive correlation. Regions below indicate a negative correlation. (D) Analysis of patient survival 
as a function of PLAUR mRNA expression in glioblastoma cases classified as mesenchymal (Mes). Kaplan-Meier 
patient survival curves were generated comparing 25% of the cases in which the tumors demonstrated the highest 
PLAUR mRNA expression levels with 25% of the cases in which the tumors demonstrated the lowest PLAUR 
mRNA expression levels. Statistical significance was determined by Log-rank test.
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Next, we established neurosphere cultures with GSC-23, TS-576, Mes, 627, GBM-6, and TS-543 glioblastoma 
cells. All six cell lines had been passaged exclusively under serum-free neurosphere conditions after isolation 
from human tumors. U87 cells also were established in neurosphere culture. U87 cells in neurosphere culture 
demonstrate increased multi-potency and capacity for self-renewal and thus, represent a model for glioblastoma 
cells with stem cell-like properties49. Representative images of neurospheres formed by the seven different cell 
types are shown in Fig. 5A.
RNA was isolated from cells in neurospheres. RT-qPCR was performed to profile expression of genes iden-
tified as biomarkers of the mesenchymal and proneural subtypes. Figure 5B shows that GSC-23 and U87 cells 
demonstrated gene expression profiles most consistent with the mesenchymal subtype. TS-543 cells demon-
strated an expression profile most consistent with the proneural subtype. The other cells showed mixed gene 
expression profiles. GSC-23 cells and U87 cells demonstrated the highest levels of mRNA for PLAUR and PLAU. 
We confirmed the PLAUR expression results, at the protein level, by immunoblot analysis. uPAR was detected in 
protein extracts from GSC-23 and U87 cells but not in comparably isolated protein extracts from the other cells 
(Fig. 5C, Supplemental Fig. 1).
Figure 3. In human glioblastomas, uPAR protein is expressed by a sub-population of the tumor cells. (A–F) 
Representative photomicrographs showing uPAR IHC with hematoxylin counterstain in randomly selected 
glioblastomas (scale bar, 50 µm). The images shown in panels A and B are from the same tumor. Panel B is 
shown to demonstrate a region of this tumor in which the density of uPAR-immunopositive cells is much higher 
than in other regions. Panel F shows a region of a glioblastoma in which the cells have adopted a spindle cell 
morphology. In this area, we also observed a higher than average number of uPAR-immunopositive cells.
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uPAR regulates expression of genes that define the mesenchymal subtype of glioblastoma. 
Because uPAR is a cell-signaling receptor9–11, we tested whether uPAR regulates expression of other genes 
that define the mesenchymal subtype in glioblastoma cells in neurospheres. First, we over-expressed uPAR in 
TS-543 cells by transfecting cells in neurospheres. Figure 6A shows that uPAR mRNA was increased more than 
30-fold (p < 0.001). uPAR protein also was increased, as determined by immunoblot analysis (Fig. 6B). uPAR 
over-expression significantly increased expression of mRNAs that are biomarkers of the mesenchymal subtype 
and decreased expression of mRNAs that are biomarkers of the proneural subtype (Fig. 6C).
Next, we blocked uPAR expression in GSC-23 cells using a PLAUR-targeting cas-9 vector. Control cells were 
transfected with a scrambled cas-9 vector. By RT-qPCR, the PLAUR-targeting cas-9 vector decreased PLAUR 
mRNA expression in GSC-23 cells in neurospheres by 75 ± 10% (Fig. 6D). uPAR protein expression also was 
decreased, as determined by immunoblot analysis (Fig. 6E). GSC-23 cells in neurospheres, in which uPAR 
expression was blocked using the cas-9 vector, demonstrated significantly decreased expression of biomark-
ers of the mesenchymal subtype and significantly increased expression of biomarkers of the proneural subtype 
(Fig. 6F).
Finally, we tested the effects of uPAR on gene expression in U87 cells in neurospheres. Figure 6G shows that 
culturing U87 cells in neurospheres substantially increased uPAR protein expression compared with that detected 
in U87 cells in monolayer culture. Silencing PLAUR gene expression with shRNA decreased PLAUR mRNA in 
U87 cells in neurospheres by 75 ± 6% (Fig. 6H). uPAR protein also was decreased (Fig. 6I). As shown in Fig. 6J, 
PLAUR gene-silencing significantly decreased expression of biomarkers that define the mesenchymal subtype and 
significantly increased expression of biomarkers that define the proneural subtype in U87 cells in neurospheres. 
Thus, in several distinct model systems, increased PLAUR expression favors the mesenchymal subtype of glioblas-
toma cell in neurospheres whereas decreased PLAUR expression favors the proneural subtype.
EGFRvIII promotes growth of neurospheres but does not negate the role of uPAR in determin-
ing glioblastoma subtype. The gene that encodes the EGF Receptor (EGFR) is over-expressed in up to 50% 
of all glioblastomas and in many of these tumors, EGFR is mutated to generate a constitutively active derivative 
called EGFRvIII50,51. U87 cells that express EGFRvIII are previously characterized and we previously demon-
strated that these cells form neurospheres52,53. To determine whether activated EGFR signaling affects glioblas-
toma neurosphere formation, we prepared neurospheres with U87 and U87vIII cells under equivalent conditions. 
Figure 7A shows that neurospheres formed by U87vIII cells grew significantly larger than neurospheres formed 
by U87 cells (p < 0.001). EGFRvIII modestly increased PLAUR expression by U87 cells in neurospheres and 
Figure 4. Database mining reveals that PLAUR mRNA is expressed selectively by glioblastoma cells that 
demonstrate a mesenchymal gene expression signature when propagated in neurospheres. (A) The dataset 
presented by Mao et al.46 was mined to generate a heatmap showing microarray gene expression data for tumor 
cells in neurospheres, established using ten separate cases of glioblastoma. Expression is shown for PLAU, 
PLAUR and genes known to serve as biomarkers of the proneural (PN) and mesenchymal (Mes) subtypes of 
stem-like cells in neurospheres. (B) Absolute mRNA expression is shown for PLAUR and PLAU in extracts 
of cells from neurospheres with mesenchymal and proneural gene expression signatures (false discovery rate 
method, ***p < 0.001).
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also increased expression of biomarkers of both the mesenchymal and proneural subtypes (Fig. 7B). However, 
EGFRvIII failed to change the gene expression profile in a manner that would suggest a change in glioblastoma 
cell subtype.
Next, we silenced PLAUR gene expression in U87vIII cells. Figure 7C confirms that PLAUR gene-silencing 
decreased uPAR protein in U87vIII cells in neurospheres. PLAUR gene-silencing also decreased expression 
of biomarkers of the mesenchymal subtype and increased expression of biomarkers of the proneural subtype 
(Fig. 7D). Thus, uPAR functions as a major regulator of glioblastoma subtype in neurosphere culture even when 
EGFR signaling is constitutively activated.
The mRNA-targeting sequence in our PLAUR-specific shRNA corresponds to nucleotides 397–419 in exon 4 
of the PLAUR gene. As a control for off-target effects, we obtained siRNA with the equivalent PLAUR-targeting 
sequence (siRNA1) and a second siRNA that targets a distinct sequence in exon 3 of the PLAUR gene (siRNA2). 
The two PLAUR-specific siRNAs and non-targeting control (NTC) siRNA were transfected into U87vIII cells 
in neurospheres. By RT-qPCR, PLAUR mRNA expression was decreased by 24 ± 9% by siRNA1 (n = 3) and by 
Figure 5. Experimental confirmation of PLAUR expression in mesenchymal glioblastoma cells in 
neurospheres. (A) Representative phase-contrast images of neurospheres formed with each of the cell types 
under investigation. (B) Heatmap comparing the relative expression of PLAUR, PLAU, and biomarkers of the 
mesenchymal (Mes) and proneural (PN) subtypes of cells in neurospheres, as determined by RT-qPCR. (C) 
Protein extracts were prepared from cells in neurospheres. Immunoblot analysis was performed to detect uPAR. 
The blot was re-probed for GAPDH as a loading control.
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Figure 6. uPAR drives expression of the mesenchymal gene signature in glioblastoma cells in neurospheres. 
(A) RT-qPCR was performed to determine relative PLAUR mRNA expression in TS-543 cells in neurospheres 
transfected with pcDNA-uPAR to over-express PLAUR or with empty vector (mean ± S.E., n = 3; student’s 
t-test, ***p < 0.001). (B) Immunoblot analysis was performed to detect uPAR in TS-543 cells in neurospheres 
transfected with pcDNA-uPAR or empty vector. GAPDH (GAP) was assessed as a loading control. (C) RT-
qPCR was performed to assess relative mRNA expression of CD44, LYN, BCL2A1, SOX2, NOTCH1 and CD133 
following transfection with pcDNA-uPAR, compared with empty vector (mean ± S.E., n = 3; student’s t-test, 
*p < 0.05). (D) RT-qPCR was performed to determine relative PLAUR expression in GSC-23 cells in neurospheres 
transfected with a PLAUR-targeting cas-9 vector or a scrambled vector (scrambled) (mean ± S.E., n = 3; student’s 
t-test ***p < 0.001). (E) Immunoblot analysis was performed to detect uPAR in GSC-23 cells in neurospheres 
transfected with the PLAUR-targeting cas-9 vector or the scrambled vector. GAPDH (GAP) was assessed as a 
loading control. (F) RT-qPCR was performed to determine relative mRNA expression of CD44, LYN, BCL2A1, 
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38% ± 3% for siRNA2. Although these levels of gene-silencing were substantially lower than those observed when 
we transfected monolayer cultures, both PLAUR-specific siRNAs generated similar changes in gene expression 
by U87vIII cells in neurospheres. Biomarkers of the mesenchymal subtype were significantly decreased and bio-
markers of the proneural subtype were increased (Supplemental Fig. 2). These results, obtained with different 
siRNAs, support the conclusion that our results with PLAUR-targeting shRNA reflect effects on uPAR expression 
and not off-target effects.
uPAR promotes glioblastoma cell survival in neurospheres. The rapid rate of growth of neu-
rospheres formed by u87vIII cells provided an opportunity to examine the effects of uPAR on the physiology 
of glioblastoma cells in neurospheres at the cellular and biochemical levels. To begin, U87vIII cells in which 
PLAUR was silenced with shRNA and cells transfected with empty vector were seeded in monolayer culture in 
serum-supplemented medium (10,000 cells/well). The increase in the number of viable cells was measured as a 
function of time by WST-1 assay. Under these conditions, PLAUR gene-silencing had no effect on cell growth at 
24, 48, or 72 h (Fig. 8A).
Next, 10–100 U87vIII cells in which PLAUR was silenced or control cells were added to each well of a 96-well 
plate and cultured in serum-free neurosphere culture medium. After 14 days, the number of neurospheres that 
formed and attained a minimum diameter of 60 μm was counted. Figure 8B shows that PLAUR gene-silencing 
significantly reduced the neurosphere count over the inoculation range compared with control cells, as deter-
mined by comparing the slopes calculated by linear regression (student’s t-test; p < 0.001). Neurospheres formed 
by PLAUR gene-silenced U87vIII cells also demonstrated a significantly decreased mean volume (Fig. 8C). A 
decrease in the frequency of neurosphere formation in a limiting dilution assay is frequently interpreted as indi-
cating a decrease in the percentage of tumor-initiating cells or cells with stem cell-like properties35,36,44; however, 
the decrease in neurosphere formation also may reflect the effects of uPAR gene-silencing on cell proliferation 
and/or survival so that neurospheres fail to achieve the 60 µm diameter threshold. Figure 8D shows that PLAUR 
gene-silencing in parental U87 cells (no EGFRvIII expression) significantly decreased the frequency of neuros-
phere formation (student’s t-test; p < 0.001), mimicking the result observed in U87vIII cells.
To determine whether PLAUR gene-silencing affects cell survival in neurospheres, first we performed TUNEL 
staining on intact neurospheres. U87vIII cells in which PLAUR was silenced with shRNA and control cells were 
compared. Figure 9A shows that TUNEL-positive cells were readily detected in neurospheres when PLAUR was 
silenced. The number of cells that were TUNEL-positive was determined as a percentage of the DAPI-stained 
nuclei. As shown in Fig. 9B, the number of TUNEL-positive cells was significantly increased in neurospheres 
formed by PLAUR gene-silenced cells (p < 0.05).
Next we isolated cells from neurospheres and quantified intracytoplasmic oligonucleosomes, which accumu-
late in apoptotic cells, by ELISA. Figure 9C shows that PLAUR gene-silencing significantly increased intracyto-
plasmic oligonucleosomes (p < 0.01). Finally, cells in neurospheres were extracted and immunoblot analysis was 
performed to detect activated caspase-3. Activated caspase-3 was increased in neurospheres formed by cells in 
which PLAUR was silenced. Taken together, these results demonstrate that uPAR promotes survival of glioblas-
toma cells within neurospheres.
Discussion
In the absence of pathological processes, PLAUR gene expression in cells in normal adult mammals is lim-
ited54–56. uPAR is detected mainly in tissue undergoing remodeling and in activated or migrating cells responding 
to injury, including inflammatory cells and activated endothelium. Many resting and quiescent cells are entirely 
uPAR-negative. PLAUR is more robustly expressed in tissues during development when the need for cell migration 
is increased, for example in the nervous system57. PLAUR gene expression also is increased in non-malignant cells 
under hypoxic conditions55,58. Under these circumstances, the ability of uPAR to promote cell survival may be very 
important. However, PLAUR gene deletion in mice does not have obvious effects on fertility or development59.
The ability of uPAR to facilitate cell survival, cell migration, and tissue invasion are exploited by cancer cells 
in diverse forms of malignancy7,54,60. By mining large TCGA datasets, we demonstrated that high levels of PLAUR 
mRNA expression are associated with a worsened prognosis in glioblastoma. Our analysis was performed with 
three distinct patient populations to assure that the correlation between high PLAUR mRNA expression and 
decreased patient survival did not reflect uPAR functioning as an indirect biomarker of glioma grade or a specific 
subtype of glioblastoma. The correlation of PLAUR mRNA expression with decreased patient survival in glioblas-
toma is particularly interesting because variability in survival in patients with this tumor is small, especially when 
SOX2, NOTCH1 and CD133 in GSC-23 cells in neurospheres transfected with the PLAUR-targeting cas-9 vector 
versus the scrambled vector (mean ± S.E., n = 3; student’s t-test **p < 0.01; *p < 0.05). (G) Immunoblot analysis 
was performed to compare uPAR and EGFR protein expression in U87 cells cultured in monolayers in serum-
supplemented medium (Adh) or in neurospheres in defined serum-free medium (NS). Actin was used as a loading 
control. (H) RT-qPCR was performed to determine relative PLAUR mRNA expression in U87 cells cultured in 
neurospheres. Cells in which uPAR gene expression was silenced with uPAR-targeting shRNA (shuPAR) and 
control cells (shCtrl) are compared (mean ± S.E., n = 3; student’s t-test ***p < 0.001). (I) Immunoblot analysis 
showing uPAR protein in U87 cells cultured in neurospheres. Cells transfected with shuPAR or shCtrl are 
compared. The blot was re-probed for actin as a loading control. (J) RT-qPCR was performed to determine relative 
mRNA expression for CD44, LYN, BCL2A1, SOX2, NOTCH1 and CD133 in U87 neurospheres transfected with 
shuPAR versus shCtrl (mean ± S.E., n = 3; student’s t-test **p < 0.01; *p < 0.05).
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GCIMP tumors are excluded29,42,43. Our analyses of patient survival did not account for patient gender, age, or 
treatment protocols. These parameters could feasibly have affected the results.
By IHC, we demonstrated that in many if not most human glioblastomas, uPAR protein is expressed at high 
levels by a small sub-population of the cells in the tumor. This finding distinguishes the pattern of uPAR expres-
sion in intact human tumors from that observed when glioblastomas are xenografted and maintained in SCID 
mice33. In the latter case, uPAR expression was homogeneously present or completely absent. Based on our IHC 
results, we propose that the effects of PLAUR mRNA expression on patient survival may reflect the activity of the 
small sub-population of uPAR-immunopositive cells in the tumor. High levels of PLAUR mRNA in a glioblas-
toma tissue sample may be observed if the density of uPAR-immunopositive cells is high. Alternatively, a high 
overall PLAUR mRNA level may be observed if the level of PLAUR mRNA is increased in the sub-population of 
uPAR-immunopositive cells.
Additional dataset mining and new experiments performed using neurosphere cell culture model systems 
provided novel insights into transitions that may occur in glioblastoma cells when these cells express high levels 
of uPAR. First, our results demonstrated that uPAR serves not only as a biomarker of the mesenchymal subtype 
of glioblastoma but also appears capable of regulating expression of other genes that, in glioblastoma cells, serve 
as biomarkers of the mesenchymal or proneural subtype. Mesenchymal stem cells that populate neurospheres 
are reported to be more aggressive when examined in in vitro assays and in intracranial xenografts in mice46. 
The effects of regulating PLAUR gene expression in TS-543, GSC-23, and U87 cells suggest that the glioblas-
toma gene expression signature and subtype may be regulated at the cellular level. It is important to note that 
PLAUR gene expression in cancers may be increased in hypoxia12. Indirectly, through its effects on PLAUR gene 
Figure 7. EGFRvIII promotes neurosphere growth but does not block the activity of uPAR in determining 
the glioblastoma cell subtype in neurosphere cultures. (A) U87 and U87vIII cells were cultured under serum-
free neurosphere forming conditions for 6 days. The mean neurosphere volume was determined (mean ± S.E.; 
n = 30; student’s t-test ***p < 0.001). (B) RT-qPCR was performed to determine relative expression of CD44, 
LYN, BCL2A1, SOX2, NOTCH1 and CD133 in U87vIII cells in neurospheres versus parental U87 cells in 
neurospheres (mean ± S.E., n = 3; student’s t-test ***p < 0.001; **p < 0.01; *p < 0.05). (C) Immunoblot analysis 
showing uPAR protein in U87vIII cells following gene silencing with shRNA (shuPAR) versus cells that express 
control shRNA (shCtrl). (D) RT-qPCR was performed to determine relative expression of CD44, LYN, BCL2A1, 
SOX2, NOTCH1 and CD133 in U87vIII cells that express shuPAR versus shCtrl in neurospheres (mean ± S.E., 
n = 3; student’s t-test **p < 0.01; *p < 0.05).
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expression, hypoxia may favor transitioning of glioblastoma cells towards the mesenchymal subtype. How uPA 
affects uPAR-signaling and gene expression in glioblastoma cells to regulate subtype remains to be determined.
In many tumors, cancer cells with mesenchymal gene expression profiles demonstrate cancer stem cell-like 
properties3,4,29. In breast cancer cells, uPAR-activated cell-signaling induces EMT and stem cell-like proper-
ties12,13,19. Glioblastoma cells with stem cell-like properties have been implicated in neurosphere formation in 
vitro and may be selected for in neurosphere culture35–37,44,45,49. It is thus intriguing that uPAR protein expression 
was substantially increased in U87 cells when these cells were cultured in neurospheres as opposed to monolay-
ers. Similarly, uPAR protein expression was substantially increased when U87vIII cells were cultured in neu-
rospheres53. These results may be interpreted to indicate that U87 and U87vIII cells that are capable of seeding 
neurospheres are uPAR-enriched. PLAUR gene-silencing in U87 and U87vIII cells decreased the frequency of 
neurosphere formation in limiting dilution assays, reflecting a decrease in the percentage of cells capable of ini-
tiating neurosphere formation, a decrease in cell proliferation within neurospheres, and/or a decrease in cell 
survival in neurospheres.
We demonstrated that uPAR promotes glioblastoma cell survival in neurospheres. Although a role for uPAR 
in cancer cell survival is previously described together with the responsible cell-signaling pathways16–18,32–34, the 
results presented here are novel for a number of reasons. First, uPAR played a key role in promoting cell survival 
in U87vIII cells despite the presence of EGFRvIII and constitutively activated EGFR signaling. In monolayer cul-
ture, uPAR functions in glioblastoma cell survival mainly after EGFR signaling is neutralized32,34. The increase in 
uPAR expression and its demonstrated role in preventing cell death in neurospheres may reflect the challenging 
microenvironment encountered by cells in neurospheres in culture medium that is serum-free. Furthermore, 
compared with cells in monolayer culture, cells in neurospheres do not benefit from matrix-binding integrins 
that activate pro-survival cell-signaling pathways and prevent a form of apoptosis called anoikis61. That uPAR may 
contribute resistance to apoptosis in cancer cells with stem cell-like properties is an exciting hypothesis.
Finally, the effects of PLAUR mRNA expression on patient survival in a tumor type in which only a small 
sub-population of the cells express uPAR protein raises the question of whether one cancer cell in a malignancy 
Figure 8. Neurosphere formation and/or growth are regulated by uPAR. (A) U87 cells and U87vIII cells that 
express control shRNA (shCtrl) or uPAR-targeting shRNA (shuPAR) were maintained in monolayer culture 
in 10% serum-containing medium for up to 72 h. The number of viable cells was quantified by WST-1 assay 
(mean ± S.E.; n = 3). (B) U87vIII cells (10–100/well) were seeded into wells under neurosphere culturing 
conditions. The number of neurospheres that achieved a minimum average diameter of 60 µm within 14 
days is shown (mean ± SEM, n = 4). The slopes from a linear regression were calculated from each individual 
experiment and determined to be significantly different by student’s t-test (***p < 0.001). (C) U87vIII cells that 
express control shRNA (shuPAR -) or PLAUR-targeting shRNA (shuPAR+) were cultured under serum-free 
neurosphere forming conditions for 6 days. Volume analysis was performed (mean ± SEM; n = 30; student’s 
t-test **p < 0.01). (D) U87 cells that express shCtrl or shuPAR were seeded into neurosphere culture medium. 
The number of neurospheres was determined as described in panel B (***p < 0.001).
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Figure 9. uPAR promotes survival of U87vIII glioblastoma cells in neurospheres. (A) Representative confocal 
fluorescent micrographs of U87vIII neurospheres stably expressing control shRNA (shCtrl) or PLAUR-targeting 
shRNA (shuPAR). The neurospheres were stained for TUNEL (green) and DAPI (blue). (B) Quantification of 
TUNEL-positive cells in control cultures (−) and in cultures of cells that express PLAUR-targeting shRNA (+). 
The ratio of TUNEL-positive cells to the total number of cells in the neurosphere was computed and is presented 
relative to that present in control cells that express shCtrl (mean ± SEM; n = 5; student’s t-test *p < 0.05). (C) 
U87vIII cells in neurospheres were extracted and studied using the Cell Death ELISA (mean ± SEM; n = 3; 
student’s t-test **p < 0.01, *p < 0.05). (D) U87vIII cells that express shuPAR or shCtrl in neurospheres were 
extracted. Immunoblot analysis was performed to detect uPAR, cleaved caspase-3 (Casp3), and actin to control 
for load.
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can make adjacent cells more aggressive. In glioblastoma, there is evidence for this phenomenon. Factors that 
may transfer from one glioblastoma cell to another and thereby increase the aggressiveness of the recipient cell 
include Interleukin-6 and Leukemia Inhibitory Factor62,63. uPAR is released in soluble form from glioblastoma 
cells that express this receptor. The soluble form of uPAR is biologically active in glioblastoma and may increase 
the aggressiveness of other cancer cells in the tumor microenvironment64.
Materials and Methods
Mining The Cancer Genome Atlas (TCGA). Microarray-based gene expression data and clinical anno-
tation for Grade II, III and IV gliomas were downloaded from the publication page in TCGA40. RNA-Seq-based 
gene expression data (RNAseq V2 RSEM) and annotation for glioblastoma patients were downloaded using cBi-
oPortal for Cancer Genomics27. The cases in each dataset were stratified into cohorts based on the level of expres-
sion of PLAUR mRNA as described. Patient survival in the various cohorts was compared. Kaplan-Meier survival 
curves were generated and analyzed using the Log-rank test to determine statistical significance.
Silhouette plots. Silhouette plots were constructed using RStudio. RNA-Seq data for 151 glioblastoma 
cases were mined27. Genes previously shown to be expressed selectively by the classical (n = 162), mesenchymal 
(n = 216), neural (n = 129), and proneural (n = 178) subtypes of glioblastoma28 were examined. Whether mRNA 
expression of each gene correlated positively or negatively with PLAUR mRNA expression in the 151 case dataset 
was calculated. Individual genes were plotted in sequence from the lowest to highest Pearson r-value to generate 
a Silhouette plot consisting of 685 separate bars.
Mining transcriptome data for glioblastoma cells propagated in neurosphere culture. Microarray- 
based gene expression data from NCBI GEO accession, GSE67089, were queried using the NCBI GEO2R profile 
graph tool to obtain sample gene expression values. Genes previously identified as biomarkers of the proneural 
and mesenchymal subtype of glioblastoma cell in neurospheres46 were analyzed in addition to PLAUR and PLAU. 
False discovery rate p-values were determined for differentially expressed genes.
Antibodies and reagents. uPAR-specific monoclonal antibody 807 (R&D Systems) was used for immu-
noblotting studies. uPAR-specific antibody for IHC was from Cell Signaling Technologies. Antibodies that rec-
ognize cleaved (activated) caspase-3 and β-actin also were from Cell Signaling Technologies. GAPDH-specific 
antibody was from Thermo-Fisher. EGFR-specific antibody was from EMD-Millipore. B27 supplement was from 
Thermo-Fisher. Basic FGF and EGF were from Sigma-Aldrich.
Cell lines and cell culture systems. U87 and HEK-293T cells were obtained from the American Type 
Culture Collection. EGFRvIII-expressing U87 cells are previously described52. All experiments were conducted 
within ten passages of the original stock. Cells were pre-screened for mycoplasma contamination using a myco-
plasma contamination kit (Lonza). GSC-23, TS-576, GBM-6 and TS-543 glioblastoma cells, which had been 
passaged exclusively in neurosphere culture, were kindly provided by Dr. Frank Furnari (UCSD Ludwig Cancer 
Center). 627 and Mes glioblastoma cells, which had been passaged exclusively in neurosphere culture, were kindly 
provided by Dr. Angelo Vescovi (University of Milan Bicocca, Milan, Italy). Neurospheres were generated from 
GSC-23, TS-576, GBM-6, TS-543, 627, and Mes cells using the NeuroCult™ NS-A Proliferation Kit (Stem Cell 
Technology). Neurospheres were generated with U87 and U87vIII cells by introducing these cells into serum-free 
medium containing DMEM-F12 with 1 × B27 supplement, basic FGF (20 ng/mL), and EGF (20 ng/mL). Cell 
lines, derived from human tissue, were studied without patient identifiers. This work was reviewed and approved 
by the UCSD Institutional Review Board as part of the Human Research Protection Program.
uPAR over-expression and repression/gene-silencing. A construct in which the full-length cDNA 
encoding human uPAR is cloned into pcDNA 3.1 (pcDNA-uPAR) and empty pcDNA 3.1 vector are previously 
described65. These plasmids were transfected into TS-543 cells in intact neurospheres (0.5 µg/106 cells) using 
Amaxa Nucleofector (Lonza), Nucleofector Solution V, and the T-020 program. After 24 h, neurospheres were 
harvested for analysis.
Stable shRNA-mediated knockdown of PLAUR in U87 and U87vIII cells was performed using the target uPAR 
sequence: 5′-AGCCGTTACCTCGAATGCA-3′, which corresponds to nucleotides 397–419 within exon 4. The 
shRNA was cloned into the transfer vector, pLKO.1. HEK-293T cells were transfected with the transfer vector and 
with two separate lentivirus packaging vectors using the Addgene third generation lentivirus production system. 
Control viral particles were constructed with empty transfer vector. Viral particles were collected from condi-
tioned medium. U87 and U87vIII cells were transduced by incubation with virus for 24 h. Cells were selected 
and maintained continuously in 1 µg/mL puromycin. Stable PLAUR knockdown was confirmed by RT-qPCR and 
immunoblot analysis 3 weeks after transduction.
PLAUR was silenced in U87vIII cells in neurospheres by siRNA transfection. PLAUR-targeting siRNA1 is pre-
viously described9 and targets the same sequence as the uPAR shRNA. PLAUR-targeting siRNA2 was a DsiRNA 
(Integrated DNA Technologies), which targets a sequence within exon 3: 5′-GCTATCGGACTGGCTTG-3′. 
Control cells were transfected with NTC On-target Plus SMARTpool siRNA (Thermo). Intact neurospheres were 
transfected with 50 nM siRNA using DharmaFECT 1 transfection reagent (General Electric), according to the 
manufacturer’s instructions.
PLAUR knockdown in GSC-23 cells in neurospheres was achieved using the CRISPR/Cas-9 system. A 
PLAUR-targeting gRNA sequence was designed to minimize off-target effects using the gRNA design tool 
from DNA 2.0. An oligonucleotide cassette was synthesized and cloned into the Cas-9 vector, pD1321-APuro 
(DNA2.0), using SAP-1 restriction sites. The oligonucleotide cassette sequence was 5′-TACACGTACT 
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AGTCGC-TGAAGCTCTTCACCGGACCACGATCGTGCGCTTGTGTTAGAAGAGCCGTCAATCGA 
GTTCGTACCT-3′. The PLAUR-targeting gRNA is underlined. The Cas-9-PLAUR vector or a pCas-9 scrambled 
control vector (Origene) was transfected into GSC-23 cells in intact neurospheres (0.5 µg/106 cells) using Amaxa 
Nucleofector (Lonza), Nucleofector Solution V, and the T-020 program. After 24 h, neurospheres were collected 
for analysis.
RT-qPCR3. Total RNA was isolated from cells in neurospheres using the NucleoSpin RNA II kit 
(Macherey-Nagel). cDNA was synthesized using the iScript cDNA synthesis kit (Bio-Rad). PCR was performed 
using TaqMan Fast Universal PCR Mastermix (Applied Biosystems) on a System 7300 Applied Biosystems instru-
ment with the following TaqMan primers and probes from Life Technologies: human PLAUR (00959822), human 
PLAU (01547054), human CD44 (01075864), human BCL2A1 (00187845), human LYN (01015816), human 
CD133 (01009257), human SOX2 (01053049), human NOTCH1 (01062014), and human HPRT1 (02800695). 
mRNA expression was standardized relative to HPRT1 mRNA using the 2−ΔΔCt method.
Immunoblot analysis. Extracts of cells were prepared in RIPA buffer (PBS, 1% Triton X-100, 0.5% sodium 
deoxycholate, and 0.1% SDS) supplemented with EDTA-free protease inhibitor mixture (Thermo Scientific). 
Protein in cell extracts was determined by bicinchoninic acid assay. Equal amounts of cell extract were loaded in 
each lane (35 μg) for SDS-PAGE. Proteins were electrotransferred to 0.45-μm PVDF membranes and incubated with 
primary antibodies followed by horseradish peroxidase-conjugated secondary antibodies. Signal was developed 
using SuperSignal West Pico (Pierce) or Femto substrate (Thermo-Fisher Scientific). For immunoblots in which 
relative band intensity is reported, at least three separate blots were subjected to densitometry using Image J.
WST-1 cell viability assay. U87vIII cells were plated at a density of 10,000 cells per well in 12 well plates in 
medium supplemented with 10% FBS. At the indicated times, WST-1 reagent was incubated with the cells for 1 h. 
Formazan dye formation was quantitated by measuring absorbance at 450 nm using a Spectramax M2 scanning 
multiwall spectrophotometer.
Neurosphere formation and growth assays. In limiting dilution neurosphere formation assays, cells 
were plated at a density of 1–100 cells per well in 96-well plates in neurosphere medium. Neurospheres were 
allowed to form undisturbed for 14 days, at which time, the number of neurospheres that achieved a minimum 
diameter of 60 µm was determined by phase contrast microscopy. Experiments were performed in triplicate. 
In each experiment, plating densities were studied in quadruplicate. Results were fit by linear regression using 
GraphPad Prism (r2 values always exceed 0.9).
For neurosphere volume analysis, U87vIII cells were suspended in neurosphere medium at a density of 10,000 
cells/cm2. Neurospheres were allowed to develop for 6 days. Neurosphere images were acquired at 100× mag-
nification. The mean radius of each neurosphere was determined using Image-J software (NIH). The volume of 
the sphere, which reports cellular content assuming close packing of the cells, was then calculated according to 
the equation: V = (4/3)πr3. All of the neurospheres in three wells were measured in three separate experiments.
Analysis of apoptosis. Neurospheres were allowed to form for 6 days. The cells were then harvested and 
apoptosis was assessed using the Roche Cell Death Detection ELISA-plus kit. Protein extracts were subjected 
to immunoblot analysis to detect activated caspase-3. In separate experiments, we analyzed apoptosis in intact 
neurospheres by TUNEL using the APO-BrdU TUNEL Assay Kit (Molecular Probes) according to the manu-
facturer’s protocol. Briefly, intact neurospheres were fixed in 4% paraformaldehyde and subjected to the TUNEL 
reaction using Br-UTP to label fragmented DNA associated with apoptosis. Apoptotic cells were detected using 
an antibody raised against BrdU. Because the cells were fixed before being exposed to Br-UTP, the BrdU antibody 
only identifies apoptotic cells and not proliferating cells in S-phase. To assess the fraction of cells undergoing 
apoptosis in intact neurospheres, 25 randomly selected neurospheres were selected for each condition. The ratio 
of TUNEL-positive cells to the total number of DAPI-stained nuclei was determined.
IHC. Tissue blocks were obtained without patient identifiers after the diagnosis of glioblastoma was confirmed 
by a neuropathologist, according to an IRB-approved protocol. Four micron-thick tissue sections were immunos-
tained with uPAR-specific antibody. Immunostaining was performed using a Ventana Discovery Ultra (Ventana 
Medical Systems, Tucson, AZ, USA). Antigen retrieval was performed using CC1 for 40 minutes at 95 °C. IHC 
staining was followed by hematoxylin counterstaining. Slides were rinsed, dehydrated though alcohol and xylene, 
and cover-slipped.
Statistics. Statistical analysis was performed using GraphPad Prism 5. All results reflect at least three inde-
pendent experiments.
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